BioSight

Therapeutics for Oncology and Hematological Disorders

Health Tech & Life Sciences
Acquired (Inactive) by Ayala Pharmaceuticals on Oct 2023 - closed due to acquisition

Company Overview

Snapshot

Founded in November 1999 by Stela Gengrinovitch, PhD and Mark Gengrinovitch, BioSight operates with 1–10 employees. The company raised a total of $62.5 million across 5 funding rounds from 9 investors. In October 2023, BioSight was acquired by Ayala Pharmaceuticals.

Business overview

BioSight is a clinical-stage biotechnology company focused on developing therapeutics for hematological malignancies and disorders. Its core product, BST-236 (INN aspacytarabine), is a proprietary anti-metabolite designed to deliver high-dose therapy with reduced systemic toxicity. The company operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical and medical biotechnology industries with a focus on drug discovery and development for oncology and hematology.

Strategic signal

In November 2022, BioSight launched a Phase 1/2 clinical trial for aspacytarabine in combination with venetoclax for first-line AML induction therapy, followed by aspacytarabine consolidation. This initiative signals the company's continued commitment to advancing its lead product and exploring combination therapies to improve outcomes for acute myeloid leukemia patients, indicating a strategic focus on expanding the therapeutic utility and market potential of BST-236.

Company Intelligence Q&A

What is BioSight's primary therapeutic focus?
BioSight is primarily focused on developing therapeutics for hematological malignancies and disorders, with its lead product, BST-236, targeting acute myeloid leukemia (AML).
When was BioSight acquired and by whom?
BioSight was acquired by Ayala Pharmaceuticals in October 2023.
What was a significant regulatory milestone for BioSight's lead product?
In June 2019, BioSight received Orphan Drug Designation from the FDA for BST-236 for the treatment of acute myeloid leukemia.
What was the latest funding round for BioSight?
In December 2020, BioSight closed a Series C financing round with participation from Israel Biotech Fund.
What clinical trial collaboration did BioSight announce in 2020?
In July 2020, BioSight announced a clinical trial collaboration with the European Cooperative Group, Groupe Francophone des Myélodysplasies.

External links